Eosinophilic colitis with favorable response to vedolizumab.
Rev Esp Enferm Dig
; 2024 Sep 05.
Article
en En
| MEDLINE
| ID: mdl-39235178
ABSTRACT
Eosinophilic gastroenteritis is a rare, chronic inflammatory disease with eosinophil infiltration in the digestive tract. Treatment typically involves corticosteroids, but new therapies, including vedolizumab, are under evaluation. Vedolizumab inhibits lymphocyte migration to intestinal tissue, impacting eosinophil activity. We report a 34-year-old male with eosinophilic colitis, dependent on corticosteroids, who showed clinical improvement with vedolizumab. Despite a mild flare-up, intensifying vedolizumab resulted in prolonged stability and reduced steroid use over seventeen months. Although corticosteroids are the primary treatment, vedolizumab shows promise in some cases, warranting further investigation to confirm its effectiveness.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Idioma:
En
Revista:
Rev Esp Enferm Dig
Asunto de la revista:
GASTROENTEROLOGIA
Año:
2024
Tipo del documento:
Article
Pais de publicación:
España